Immunic Reports Q2 2025 Financial Results with Vidofludimus Calcium Progress

Immunic, Inc. detailed significant advances in its development programs in the second quarter of 2025. Notably, its lead compound, vidofludimus calcium, demonstrated promising results in multiple sclerosis trials. The Phase 2 CALLIPER trial showed a 23.8% reduction in confirmed disability worsening in progressive MS patients. Additionally, enrollment for the Phase 3 ENSURE trials in relapsing MS was completed, with top-line results expected by the end of 2026.

Financially, Immunic strengthened its position with $70.1 million from recent financings, aiming to support ongoing and future trials. However, rising R&D expenses led to a net loss of $27 million for Q2 2025. As of June 30, 2025, cash reserves of $55.3 million require further funding to sustain operations.

As the company prepares for continued trials of vidofludimus calcium and IMU-856, prospects appear cautiously optimistic, contingent on financing strategies and trial outcomes.